CluePoints announced that Ken Getz, Executive Director and Professor at Tufts CSDD, will be speaking at RBQMLive on October 7, 2026, discussing how regulatory developments, AI, and oversight expectations redefine the RBQM landscape.

CluePoints is the premier provider of RBQM and data quality oversight software. We’re leveraging the potential of AI using advanced statistics and ML to determine the quality, accuracy, and integrity of clinical trial data both during and after the study. Aligned with guidance from the FDA, EMA, ICH, and MHRA, CluePoints supports central and on-site monitoring, medical review, and quality risk management to drive a holistic risk-based strategy. Coupled with thought leadership and consulting expertise to aid risk assessment and solution implementation, the result is positive clinical development outcomes, increased operational efficiency, lower costs, and reduced regulatory submission risk as part of the industry paradigm shift to RBQM. To learn more about CluePoints, visit CluePoints.com.